ArticleAdvanced healthcare materials2026
Injectable Stimuli-Responsive Amphiphilic Hydrogel for Rapid Hemostasis, Robust Tissue Adhesion, and Controlled Drug Delivery in Trauma and Surgical Care.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Uncontrolled bleeding in trauma and surgical settings requires rapid, minimally invasive materials that can effectively stop bleeding and provide durable wound sealing. Here, we introduce an injectable, pH-responsive amphiphilic hydrogel designed for quick hemostasis, strong wet-tissue adhesion, and controlled therapeutic release. The hydrogel is prepared via a mild nucleophilic substitution reaction between tertiary amines of Poly(2-(dimethylamino)ethyl methacrylate (PDMA) and gallic acidfunctionalized branched polyethyleneimine PEI(GA), using chloride-terminated Pluronic F-127 (Cl-Plu-Cl) as a crosslinker. The shear-thinning, uniform prepolymer allows for consistent laparoscopic delivery and rapidly gels in situ (∼54 seconds) across a physiological pH range (5.07.4). In vitro and in vivo tests, including a mouse liver hemorrhage model, showed a 61% reduction in blood loss, comparable to Truseal (∼63%), while providing better injectability, biocompatibility, flexibility, and adjustable degradation and gelation properties. The (Cl-Plu-Cl/PDMA/PEI(GA)) hydrogel demonstrates strong adhesion strength (∼47 kPa) and withstands burst pressures up to 220 mmHg, exceeding typical arterial blood pressure. Sustained, pH-responsive release of amoxicillin (∼60% at pH 7.4 and ∼98% at pH 5.0 over 80 hours) displayed antibacterial activity against Staphylococcus aureus and MRSA. Alamar Blue and Live/Dead assays confirmed over 90% cell viability, and the gradual in vitro degradation over three weeks indicates safe resorption and potential for clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.